Minerva Neurosciences Stock Alpha and Beta Analysis
| NERV Stock | USD 3.92 0.10 2.49% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Minerva Neurosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Minerva Neurosciences over a specified time horizon. Remember, high Minerva Neurosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Minerva Neurosciences' market risk premium analysis include:
Beta 3.79 | Alpha 1.73 | Risk 19.17 | Sharpe Ratio 0.11 | Expected Return 2.05 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Minerva Neurosciences Backtesting, Minerva Neurosciences Valuation, Minerva Neurosciences Correlation, Minerva Neurosciences Hype Analysis, Minerva Neurosciences Volatility, Minerva Neurosciences History and analyze Minerva Neurosciences Performance. Minerva Neurosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Minerva Neurosciences market risk premium is the additional return an investor will receive from holding Minerva Neurosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Minerva Neurosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Minerva Neurosciences' performance over market.| α | 1.73 | β | 3.79 |
Minerva Neurosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Minerva Neurosciences' Buy-and-hold return. Our buy-and-hold chart shows how Minerva Neurosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Minerva Neurosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Minerva Neurosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Minerva Neurosciences shares will generate the highest return on investment. By understating and applying Minerva Neurosciences stock market price indicators, traders can identify Minerva Neurosciences position entry and exit signals to maximize returns.
Minerva Neurosciences Return and Market Media
The median price of Minerva Neurosciences for the period between Sun, Oct 5, 2025 and Sat, Jan 3, 2026 is 3.88 with a coefficient of variation of 22.75. The daily time series for the period is distributed with a sample standard deviation of 0.84, arithmetic mean of 3.69, and mean deviation of 0.62. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | How buybacks impact Minerva Neurosciences Inc. stock value - Analyst Upgrade Free Real-Time Market Sentiment Alerts - newser.com | 10/17/2025 |
2 | Minerva Neurosciences Q3 Earnings Snapshot | 11/05/2025 |
3 | ProMIS Neurosciences price target lowered by 1 at Guggenheim, heres why PMN | 11/18/2025 |
4 | Minerva appoints Kaul to board of directors NERV | 11/19/2025 |
5 | ProMIS Neurosciences to execute 1-for-25 reverse stock split | 11/24/2025 |
6 | ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimers trials, Supporting its Ongoing Pha... | 12/01/2025 |
7 | Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum | 12/03/2025 |
8 | Aidoc Deepens Clinical AI Leadership Through Strategic Partnerships in Neurosciences | 12/16/2025 |
9 | ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimers Disease | 12/18/2025 |
10 | Acquisition by Remy Luthringer of 2250000 shares of Minerva Neurosciences at 3.98 subject to Rule 16b-3 | 12/22/2025 |
11 | Join Jupiter Neurosciences Exclusive Live Investor Webinar and QA Session on January 6 | 12/23/2025 |
12 | Gains Recap Why Minerva Neurosciences Inc stock is in analyst buy zone - Product Launch Free Expert Verified Stock Movement Alerts - moha.gov.vn | 12/30/2025 |
About Minerva Neurosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Minerva or other stocks. Alpha measures the amount that position in Minerva Neurosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2025 | 2026 (projected) | Interest Debt Per Share | 7.68 | 8.06 | Revenue Per Share | 7.26 | 6.46 |
Minerva Neurosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Minerva Neurosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Minerva Neurosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Minerva Neurosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Minerva Neurosciences. Please utilize our Beneish M Score to check the likelihood of Minerva Neurosciences' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Minerva Neurosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.